Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials DOI Creative Commons

Linxuan Wu,

Chuan He,

Tingting Zhao

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: June 25, 2024

Abstract Locally advanced breast cancer (LABC) is a heterogeneous group of that accounts for 10–30% cases. Despite the ongoing development current treatment methods, LABC remains severe and complex public health concern around world, thus prompting urgent requirement innovative diagnosis strategies. The primary challenges are inoperable clinical status ineffective local control methods. With rapid advancement nanotechnology, inorganic nanoparticles (INPs) exhibit potential application prospect in diagnosing treating cancer. Due to unique inherent characteristics INPs, different functions can be performed via appropriate modifications constructions, making them suitable imaging technology strategies schemes. INPs improve efficacy conventional radiotherapy treatment. In face LABC, have proposed new therapeutic methods fostered evolution novel such as photothermal photodynamic therapy, magnetothermal sonodynamic multifunctional nanoplatform. This article reviews advances accurate offers insights overcome existing difficulties management. Graphical

Language: Английский

Current advances in niosomes applications for drug delivery and cancer treatment DOI Creative Commons

Ali Moammeri,

Masoumeh Mirzaei Chegeni,

Hamidreza Sahrayi

et al.

Materials Today Bio, Journal Year: 2023, Volume and Issue: 23, P. 100837 - 100837

Published: Oct. 21, 2023

The advent of nanotechnology has led to an increased interest in nanocarriers as a drug delivery system that is efficient and safe. There have been many studies addressing nano-scale vesicular systems such liposomes niosome newer generation nanocarriers. niosomes provide multilamellar carrier for lipophilic hydrophilic bioactive substances the self-assembled vesicle, which are composed non-ionic surfactants conjunction with cholesterol or other amphiphilic molecules. These surfactant vesicles, simply known niosomes, can be utilized wide variety technological applications. As alternative liposomes, considered more chemically physically stable. methods preparing economic. Many reports discussed terms their physicochemical properties applications systems. carriers, nano-sized expand horizons pharmacokinetics, decreasing toxicity, enhancing solvability bioavailability. In this review, we review components fabrication well functionalization, characterization, administration routes, cancer gene delivery, natural product delivery. We also discuss limitations challenges development future perspective niosomes.

Language: Английский

Citations

67
Doxorubicin-loaded Niosomes functionalized with gelatine and alginate as pH-responsive drug delivery system: A 3D printing approach DOI Creative Commons
Mohammad Zaer, Alaa Moeinzadeh, Hossein Abolhassani

et al.

International Journal of Biological Macromolecules, Journal Year: 2023, Volume and Issue: 253, P. 126808 - 126808

Published: Sept. 9, 2023

Despite many efforts, breast cancer remains one of the deadliest cancers and its treatment faces challenges related to drug side effects metastasis. Combining 3D printing nanocarriers has created new opportunities in treatment. In this work, 3D-printed gelatin-alginate nanocomposites containing doxorubicin-loaded niosomes (Nio-DOX@GT-AL) were recruited as an advanced potential pH-sensitive delivery system. Morphology, degradation, release, flow cytometry, cell cytotoxicity, migration, caspase activity, gene expression controls (Nio-DOX Free-DOX) evaluated. Results show that obtained niosome a spherical shape size 60-80 nm. Sustained release biodegradability presented by Nio-DOX@GT-AL Nio-DOX. Cytotoxicity analysis revealed engineered scaffold had 90 % cytotoxicity against cells (MCF-7), whereas exhibited <5 non-tumor line (MCF-10A), which was significantly more than antitumor effect control samples. Scratch-assay indicator migration demonstrated reduction almost 60 covered surface. Gene could provide explanation for nanocarriers, reduced metastasis-promoting genes (Bcl2, MMP-2, MMP-9), enhanced activity promote apoptosis (CASP-3, CASP-8, CASP-9). Also, considerable inhibition metastasis-associated (Bax p53) observed. Moreover, flow-cytometry data decreased necrosis drastically. The findings research can confirm employing 3D-printing niosomal formulation be effective strategy designing novel efficient applications.

Language: Английский

Citations

28
Niosomes for nose-to-brain delivery: A non-invasive versatile carrier system for drug delivery in neurodegenerative diseases DOI

Alaa Raad Al Jayoush,

Hatem A. F. M. Hassan,

Hawraa Asiri

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2023, Volume and Issue: 89, P. 105007 - 105007

Published: Sept. 28, 2023

Language: Английский

Citations

28
Design of New Daunorubicin Derivatives with High Cytotoxic Potential DOI Open Access

Aleksandra A. Kalashnikova,

Altynkul Toibazarova,

Оleg I. Аrtyushin

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1270 - 1270

Published: Jan. 31, 2025

Chemotherapy with anthracycline antibiotics is a common method of treating tumors various etiologies. To create more highly effective cytostatics based on daunorubicin, we used the reductive amination using polyalkoxybenzaldehydes. The obtained derivatives structure have much greater cytotoxicity compared to daunorubicin due increased affinity for DNA, ability disrupt cell cycle, and their inhibition glycolysis process, which confirmed by data from extensive biological studies results molecular modeling.

Language: Английский

Citations

1
Nano-drug Delivery System: a Promising Approach Against Breast Cancer DOI Creative Commons
Jonaid Ahmad Malik,

Jeba Ajgar Ansari,

Sakeel Ahmed

et al.

Therapeutic Delivery, Journal Year: 2023, Volume and Issue: 14(5), P. 357 - 381

Published: May 1, 2023

Breast cancer (BC) is among the most frequent malignancies women face around globe. Nanotherapeutics are constantly evolving to overcome limitations of conventional diagnostic and therapeutic approaches. Nanotechnology-based nanocarriers have a higher entrapment efficiency, low cytotoxicity, greater stability improved half-life than therapy. Nano-drug delivery systems pharmacokinetics pharmacodynamics parameters because nanomeric size. Currently, various nano-formulations in preclinical clinical settings for breast cancer, like polymeric nanoparticles, micelles, nanobodies, magnetic liposomes, niosomes, gold-nanoparticles, dendrimers carbon-nanotubes. This review highlights recent advancement developing nano-drug BC treatment. will open gateway researchers understand current approaches nano-formulation improving problems associated with

Language: Английский

Citations

22
A comparison study between doxorubicin and curcumin co-administration and co-loading in a smart niosomal formulation for MCF-7 breast cancer therapy DOI Creative Commons
Shaghayegh Saharkhiz, Atefeh Zarepour, Negar Nasri

et al.

European Journal of Pharmaceutical Sciences, Journal Year: 2023, Volume and Issue: 191, P. 106600 - 106600

Published: Oct. 5, 2023

Chemotherapy agents often exhibit limited effectiveness due to their fast elimination from the body and non-targeted delivery. Emerging nanomaterials as drug delivery carriers open new expectancy overcome these limitations in current chemotherapeutic treatments. In this study, we introduce evaluate a smart pH-responsive niosomal formulation capable of delivering Doxorubicin (DOX) Curcumin (CUR) both individually co-loaded forms. particular, drug-loaded niosomes were prepared using thin-film hydration method then characterized via different physicochemical analyses. The pH responsivity carrier was assessed by performing release study three conditions (4, 6.5, 7.4). Finally, anticancer efficacy therapeutic compounds evaluated through MTT assay. Our results showed spherical particles with size about 200 nm -2 mV surface charge. Encapsulation efficiency (EE%) nanocarrier 77.06 % 79.08 for DOX CUR, respectively. confirmed carrier. assay revealed 39 43 cell deaths after treatment cur-loaded dox-loaded niosomes, which increased 74 79 co-administration co-loading forms drugs, respectively, exhibiting selectively CUR or combination. Overall, findings suggest that our nanoformulation holds potential targeted highly effective approach cancer management therapy, overcoming conventional chemotherapy drugs.

Language: Английский

Citations

19
Targeted drug release and in vitro anticancer activities of iron oxide@folic acid/chitosan-based nano-niosomes DOI

K. Parvathi,

Mookkandi Palsamy Kesavan, S.K. Ashok Kumar

et al.

Colloids and Surfaces A Physicochemical and Engineering Aspects, Journal Year: 2024, Volume and Issue: 686, P. 133366 - 133366

Published: Feb. 2, 2024

Language: Английский

Citations

6
Evaluating a targeted Palbociclib-Trastuzumab loaded smart niosome platform for treating HER2 positive breast cancer cells DOI Creative Commons
Shaghayegh Saharkhiz, Negar Nasri, Nazanin Naderi

et al.

International Journal of Pharmaceutics X, Journal Year: 2024, Volume and Issue: 7, P. 100237 - 100237

Published: March 11, 2024

In this study, we present a targeted and pH-sensitive niosomal (pHSN) formulation, incorporating quantum dot (QD)-labeled Trastuzumab (Trz) molecules for the specific delivery of Palbociclib (Pal) to cells overexpressing human epidermal growth factor receptor 2 (HER2). FTIR analyses confirmed successful preparation pHSNs their bioconjugation. The labeled Trz-conjugated Pal-pHSNs (Trz-Pal-pHSNs) exhibited size approximately 170 nm, displaying spherical shape with neutral surface charge −1.2 mV. Pal encapsulation reached ~86%, release pattern followed two-phase pH-dependent mechanism. MTT assessments demonstrated enhanced apoptosis induction, particularly in HER2-positive cells, by Trz-Pal-pHSNs. Fluorescence imaging further validated internalization particles into cells. conclusion, Trz-Pal-pHSNs emerge as promising platform personalized medicine treatment breast cancer.

Language: Английский

Citations

6
A comprehensive review of the biomaterial-based multifunctional nanocarriers for therapeutic applications in breast cancer DOI

Arti Shettiwar,

Ujala Gupta, Priti Paul

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2023, Volume and Issue: 89, P. 104990 - 104990

Published: Sept. 29, 2023

Language: Английский

Citations

12
A Comprehensive Review on Niosomes as a Tool for Advanced Drug Delivery DOI
Shivani Sharma, Akash Garg, Rutvi Agrawal

et al.

Pharmaceutical Nanotechnology, Journal Year: 2023, Volume and Issue: 12(3), P. 206 - 228

Published: July 27, 2023

Over the past few decades, advancements in nanocarrier-based therapeutic delivery have been significant, and niosomes research has recently received much interest. The self-assembled nonionic surfactant vesicles lead to production of niosomes. most recent nanocarriers, niosomes, are made surfactants with or without proper quantities cholesterol other amphiphilic molecules. Because their durability, low cost components, largescale production, simple maintenance, high entrapment efficiency, being used more frequently. Additionally, they enhance pharmacokinetics, reduce toxicity, solubility poorly water-soluble compounds, & increase bioavailability. One crucial features is controlled release targeted diffusion, which utilized for treating cancer, infectious diseases, problems. In this review article, we covered all fundamental information about including preparation techniques, types, factors influencing formation, evaluation, applications, administration routes, along developments.

Language: Английский

Citations

11